(Total Views: 468)
Posted On: 08/30/2021 12:01:35 AM
Post# of 1460
Avxl now has 3 P3 trials underway.The biggy is an Alzheimer's trial with 509 subjects due to finish late this year so top line result by EOY.
There are two Rett syndrome trials underway. One for pediatric and one for adult Rett sufferers. The pediatric trial had received Rare Pediatric Disease designation, fast track designation, and Orphan drug designations.
The company recently completed a P2/3 trial for Parkinson's disease dementia with very good top line results.
Anavex has $157 million cash in the bank and no long term debt.
I suggest that people take a good look at Anavex. I own a chunk and expect to hold it at least through 2023 when the share price should be in excess of $100/sh. If the FDA approves it drug for Alzheimer's it will be more than $100/sh by a considerable margin.
There are two Rett syndrome trials underway. One for pediatric and one for adult Rett sufferers. The pediatric trial had received Rare Pediatric Disease designation, fast track designation, and Orphan drug designations.
The company recently completed a P2/3 trial for Parkinson's disease dementia with very good top line results.
Anavex has $157 million cash in the bank and no long term debt.
I suggest that people take a good look at Anavex. I own a chunk and expect to hold it at least through 2023 when the share price should be in excess of $100/sh. If the FDA approves it drug for Alzheimer's it will be more than $100/sh by a considerable margin.
(1)
(0)
